BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsCompany update

CRANBURY, N.J. --(BUSINESS WIRE)--Feb. 23, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the

Open original release

Related news

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

KPTIKaryopharm Therapeutics2026-05-12 11:30 EST

Karyopharm to Participate at Upcoming Investor Conferences

NTLAIntellia2026-05-05 11:30 EST

Intellia Therapeutics to Participate in Upcoming Investor Conferences

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

ARWRArrowhead Pharmaceuticals2026-05-04 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

CAPRCapricor Therapeutics2026-06-08 13:25 EST

Capricor Therapeutics to Present at Upcoming Investor Conferences

View all latest news

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a gene-therapy company focused on rare pediatric and hematologic diseases. Its story is built around using advanced genetic medicine to address severe inherited conditions.

Recent company news

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKTRocket Pharmaceuticals2026-03-27 11:00 EST

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-02-23 12:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Stock data

Close
3.25 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States